| Digestive System Neoplasms |
| Active, not recruiting | 3 | 788 | Europe | cisplatin+capecitabine, radiotherapy, epirubicin+cisplatin+capecitabine | Dutch Colorectal Cancer Group, The Netherlands Cancer Institute, Roche Pharma AG | Gastric Cancer | 12/18 | 12/25 | | |
NCT00962520: Tarceva With Chemoradiation and Adjuvant Chemotherapy for Resectable Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 40 | US | Erlotinib, Tarceva, capecitabine, Xeloda, Radiation Therapy, gemcitabine, Gemzar, erlotinib | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Genentech, Inc. | Pancreatic Cancer | 04/22 | 04/23 | | |
|
|
OCCLURANDOM, NCT02230176: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II |
|
|
| Recruiting | 2 | 80 | Europe | Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Advanced Accelerator Applications | Pancreatic Neuroendocrine Carcinoma | 10/23 | 10/23 | | |
NCT01728051: Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver |
|
|
| No Longer Available | N/A | | US | Melphalan, Percutaneous Hepatic Perfusion | Delcath Systems Inc. | Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma | | | | |
NCT02082691: Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma |
|
|
| No Longer Available | N/A | | US | G-202 | Devalingam Mahalingam, GenSpera, Inc. | Hepatocellular Carcinoma | | | | |
NCT01646593: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy |
|
|
| No Longer Available | N/A | | US | Regorafenib (BAY73-4506) | Bayer | Gastrointestinal Stromal Tumors | | | | |
NCT01613053: Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination |
|
|
| No Longer Available | N/A | | RoW | Glivec | Novartis Pharmaceuticals | Gastrointestinal Stromal Tumor | | | | |
NCT01689376: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program) |
|
|
| No Longer Available | N/A | | RoW | Regorafenib (BAY73-4506) | Bayer | Gastrointestinal Stromal Tumors | | | | |